Cargando…

Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial

OBJECTIVE: To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction. METHODS: This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Long, Qi, Lijuan, Fu, Jinhua, Bi, Shuqin, Li, Lin, Fu, Yinghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450415/
https://www.ncbi.nlm.nih.gov/pubmed/34552510
http://dx.doi.org/10.3389/fphys.2021.737878
_version_ 1784569640880439296
author Zhao, Long
Qi, Lijuan
Fu, Jinhua
Bi, Shuqin
Li, Lin
Fu, Yinghui
author_facet Zhao, Long
Qi, Lijuan
Fu, Jinhua
Bi, Shuqin
Li, Lin
Fu, Yinghui
author_sort Zhao, Long
collection PubMed
description OBJECTIVE: To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction. METHODS: This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial alloimmune disorders. A total of 201 women were enrolled, all of whom had at least 3 serial abortions and endometrial alloimmune dysfunction. Participants were randomly assigned to two groups. The CsA group (n = 101) received intrauterine infusion of 250 mg CsA on the 3rd and 7th days after menstruation for 2 menstrual cycles, while the placebo group (n = 100) received placebo. The birth of healthy, deformity-free babies was the main study outcome. RESULTS: In total, 75 (74.26%) women in the CsA group and 59 (59.00%) women in the placebo group gave birth to healthy babies [P = 0.01, OR = 2.01; 95% CI (1.10∼3.65)]. Compared to the placebo group, the CsA group had dramatically lower endometrial CD56(+) cell and CD57(+) cell concentrations at the luteal phase of the second menstrual cycle (P < 0.05). CONCLUSION: Intrauterine perfusion of CsA was confirmed to be a promising approach for the treatment of intractable alloimmune RSA.
format Online
Article
Text
id pubmed-8450415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84504152021-09-21 Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial Zhao, Long Qi, Lijuan Fu, Jinhua Bi, Shuqin Li, Lin Fu, Yinghui Front Physiol Physiology OBJECTIVE: To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction. METHODS: This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial alloimmune disorders. A total of 201 women were enrolled, all of whom had at least 3 serial abortions and endometrial alloimmune dysfunction. Participants were randomly assigned to two groups. The CsA group (n = 101) received intrauterine infusion of 250 mg CsA on the 3rd and 7th days after menstruation for 2 menstrual cycles, while the placebo group (n = 100) received placebo. The birth of healthy, deformity-free babies was the main study outcome. RESULTS: In total, 75 (74.26%) women in the CsA group and 59 (59.00%) women in the placebo group gave birth to healthy babies [P = 0.01, OR = 2.01; 95% CI (1.10∼3.65)]. Compared to the placebo group, the CsA group had dramatically lower endometrial CD56(+) cell and CD57(+) cell concentrations at the luteal phase of the second menstrual cycle (P < 0.05). CONCLUSION: Intrauterine perfusion of CsA was confirmed to be a promising approach for the treatment of intractable alloimmune RSA. Frontiers Media S.A. 2021-09-06 /pmc/articles/PMC8450415/ /pubmed/34552510 http://dx.doi.org/10.3389/fphys.2021.737878 Text en Copyright © 2021 Zhao, Qi, Fu, Bi, Li and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Zhao, Long
Qi, Lijuan
Fu, Jinhua
Bi, Shuqin
Li, Lin
Fu, Yinghui
Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title_full Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title_fullStr Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title_full_unstemmed Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title_short Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial
title_sort efficacy of intrauterine perfusion of cyclosporin a for intractable recurrent spontaneous abortion patients with endometrial alloimmune disorders: a randomized controlled trial
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450415/
https://www.ncbi.nlm.nih.gov/pubmed/34552510
http://dx.doi.org/10.3389/fphys.2021.737878
work_keys_str_mv AT zhaolong efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial
AT qilijuan efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial
AT fujinhua efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial
AT bishuqin efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial
AT lilin efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial
AT fuyinghui efficacyofintrauterineperfusionofcyclosporinaforintractablerecurrentspontaneousabortionpatientswithendometrialalloimmunedisordersarandomizedcontrolledtrial